This partnership underscores BeniComp's commitment to proactive and preventive health management, enabling an even broader reach of their transformative health insurance products.
'Integrating GRAIL's groundbreaking multi-cancer early detection technology into BeniComp's plans is a step forward in our mission to impact the root cause of diseases and high costs,' said
BeniComp's program offers an innovative approach to controlling health costs by identifying risks at an early stage. The inclusion of GRAIL's pioneering MCED screening test will now further enhance these preventive health measures by facilitating early detection of a shared cancer signal across more than 50 types of cancer from a single blood draw.
GRAIL's Galleri test is a first-of-its-kind MCED test introduced in 2021. Utilizing breakthroughs in next-generation sequencing and machine learning, the Galleri test can detect a signal shared by many cancers, including those currently without recommended screenings. Adding Galleri to guideline recommended cancer screenings may help to detect more cancers at an early stage and facilitate early diagnosis and treatment when necessary.
'Cancer remains the leading cause of death worldwide and this is because we are finding many cancers too late. Multi-cancer early detection offers a new approach for screening people that can find a signal shared by multiple cancers before symptoms appear, in early stages,' said
About BeniComp
Founded in 1962, BeniComp is a leader in preventive health solutions, offering innovative health plans that drive engagement, improve health outcomes, and often save groups millions of dollars per year. Their programs have helped participants reverse chronic diseases and even come off their medications.
About GRAIL
GRAIL is a healthcare company whose mission is to detect cancer early, when it can be cured. GRAIL is focused on alleviating the global burden of cancer by developing pioneering technology to detect and identify multiple deadly cancer types early. The company is using the power of next-generation sequencing, population-scale clinical studies, and state-of-the-art computer science and data science to enhance the scientific understanding of cancer biology, and to develop its multi-cancer early detection blood test. GRAIL is headquartered in
About Galleri
The Galleri multi-cancer early detection test can detect a signal shared by more than 50 types of cancer, as defined by the
Important Galleri Safety Information
The Galleri test is recommended for use in adults with an elevated risk for cancer, such as those aged 50 or older. The Galleri test does not detect all cancers and should be used in addition to routine cancer screening tests recommended by a healthcare provider. Galleri is intended to detect cancer signals and predict where in the body the cancer signal is located. Use of Galleri is not recommended in individuals who are pregnant, 21 years old or younger, or undergoing active cancer treatment.
Results should be interpreted by a healthcare provider in the context of medical history, clinical signs and symptoms. A test result of 'Cancer Signal Not Detected' does not rule out cancer. A test result of 'Cancer Signal Detected' requires confirmatory diagnostic evaluation by medically established procedures (e.g. imaging) to confirm cancer.
If cancer is not confirmed with further testing, it could mean that cancer is not present or testing was insufficient to detect cancer, including due to the cancer being located in a different part of the body. False-positive (a cancer signal detected when cancer is not present) and false-negative (a cancer signal not detected when cancer is present) test results do occur.
Laboratory/Test Information
GRAIL's clinical laboratory is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA) and accredited by the
Contact:
Email: pr@grail.com
Email: ir@grail.com
(C) 2024 Electronic News Publishing, source